<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01956201</url>
  </required_header>
  <id_info>
    <org_study_id>146MHL13011</org_study_id>
    <nct_id>NCT01956201</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin</brief_title>
  <official_title>Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin in Mixed Hypercholesterolemic Patient: Multi Center, Randomized, Double-blind, Parallel-group, Therapeutic Confirmatory Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Atorvastatin and
      Fenofibrate compared with atorvastatin monotherapy in mixed hypercholesterolemic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi center, randomized, double-blind, parallel-group, therapeutic confirmatory study

      Primary Outcome Measure:

      The mean percent change of Non-HDL Cholesterol [Time Frame: from baseline at week 8]

      Secondary Outcome Measures:

      The achievement rate of LDL-C&lt;100mg/dl, Non-HDL-C&lt;130mg/dl [Time Frame: from baseline at week
      8] The mean percent change of LDL-C, HDL-C, TG, TC, Apo-AI, Apo-B [Time Frame: from baseline
      at week 4, 8] The mean percent change of Non-LDL-C/HDL-C, TC/HDL-C, LDL-C/HDL-C, Apo-B/Apo-AI
      [Time Frame: from baseline at week 4, 8] The mean percent change of Fibrinogen, hs-CRP [Time
      Frame: from baseline at week 4, 8] Safety evaluation [Time Frame: Treatment period and
      Extension period]
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean percent change of Non-HDL Cholesterol</measure>
    <time_frame>from baseline at week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The achievement rate of LDL-C&lt;100mg/dl, Non-HDL-C&lt;130mg/dl</measure>
    <time_frame>from baseline at week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percent change of LDL-C, HDL-C, TG, TC, Apo-AI, Apo-B</measure>
    <time_frame>from baseline at week 4, 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percent change of Non-LDL-C/HDL-C, TC/HDL-C, LDL-C/HDL-C, Apo-B/Apo-AI</measure>
    <time_frame>from baseline at week 4, 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percent change of Fibrinogen, hs-CRP</measure>
    <time_frame>from baseline at week 4, 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation (Physical examination, Vital sign, Laboratory, AE etc.)</measure>
    <time_frame>Treatment period (8 weeks) and Extension period (16 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">476</enrollment>
  <condition>Mixed Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Atorvastatin 20mg, Fenofibrate 160mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin 20mg, Fenofibrate 160mg: po, q.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 20mg, Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin 20mg, Placebo for Fenofibrate 160mg po, q.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 20mg</intervention_name>
    <description>[Atorvastatin Run-in Period] Take Atorvastatin 20mg 1 tablet once a day (after breakfast) [Treatment Period] Take Atrovastatin 20mg/Fenofibrate 160mg or Atorvastiatin 20mg/Placebo of Finofibrate 160mg 2 tablet once a day (after breakfast) [Extension Period] Take Atrovastatin 20mg, Fenofibrate 160mg 2 tablet once a day (after breakfast)</description>
    <arm_group_label>Atorvastatin 20mg, Fenofibrate 160mg</arm_group_label>
    <arm_group_label>Atorvastatin 20mg, Placebo</arm_group_label>
    <other_name>Lipilou Tab.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate 160mg</intervention_name>
    <description>Refer to Intervention Description of Atorvastatin 20mg</description>
    <arm_group_label>Atorvastatin 20mg, Fenofibrate 160mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo (Fenofibrate 160 mg)</intervention_name>
    <description>Refer to Intervention Description of Atorvastatin 20mg</description>
    <arm_group_label>Atorvastatin 20mg, Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;19 years old

          -  High risk patient to Coronary Heart Disease (applied to 1 or more CHD risk factor
             listed below)

               1. Patient with Coronary Heart Disease

               2. Patient with carotid artery disease, peripheral blood vessel disease, abdominal
                  aneurysm

               3. Patient with diabetes(HbA1C≤9.0%)

               4. 10-year risk of CHD &gt;20%(by Framingham 10-year risk score calculation)

          -  At Visit 1(Screening)

               1. 100mg/dl≥LDL-C, 150mg/dl≤TG≤500mg/dl

                    -  4weeks of Atorvastatin 20mg monotherapy run-in period

               2. LDL-C&lt;100mg/dl, 150mg/dl≤TG≤500mg/dl

                    -  If treated with Atorvastatin 20mg monotherapy 4weeks prior to this study

          -  At Visit 2(After 4weeks of Atorvastatin monotherapy run-in period)

               -  LDL&lt;100mg/dl, 150mg/dl≤TG≤500mg/dl

        Exclusion Criteria:

          -  Patients with acute artery disease within 3 months

          -  Patients with congestive heart failure(NYHA class III~IV) or uncontrolled arrhythmia
             within 6 months

          -  Patients with uncontrolled hypertension(SBP&gt;160mmHg or DBP&gt;95mmHg)

          -  TSH&gt;1.5X ULN

          -  Patients with myopathy, rhabdomyolysis or CK&gt;2X ULN

          -  Hypersensitive to Atorvastatin and/or Fenofibrate or had photoallergy or phototoxicity
             during fibrate and/or ketoprofen treatment

          -  Serum Creatinine&gt;2.5mg/dl, AST or ALT &gt; 2X ULN

          -  History of drug or alcohol abuse within 6 months

          -  History of GI tract surgery or disability to drug absorption

          -  Women with pregnant, breast-feeding

          -  Patients with gallbladder disease

          -  Patients with biliary cirrhosis

          -  Patients with pancreatitis(acute pancreatitis is excluded due to severe
             hypertriglyceridemia)

          -  Patients treated with any investigational drugs within 4 weeks at the time consents
             are obtained

          -  History of malignant tumor including leukemia, lymphoma within 5 years

          -  Patients must be treated with medications prohibited for concomitant use during study
             period

          -  Not eligible to participate for the study at the discretion of investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MoonKyu Lee, M.D. , Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center - Seoul</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyun-Kyung Oh</last_name>
    <phone>82-2-2194-0469</phone>
    <email>hkoh@ckdpharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DaeKyung Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sangsu Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kangwon University Hospital</name>
      <address>
        <city>Chuncheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yonghoon Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hosang Son</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HoChan Cho</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Konyang University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jangho Bae</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YoungKun Ahn</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dongguk University Ilsan Hospital</name>
      <address>
        <city>Ilsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KyungAh Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inje University Ilsan Paik Hospital</name>
      <address>
        <city>Ilsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SungYoon Lee</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaegun Chae</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hanyang University Guri Hospital</name>
      <address>
        <city>Kyunggi</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changmum Lee</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital, Bundang</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soo Lim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kihoon Han</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eulji General Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KyungAh Han</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Youngwon Yoon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KiChul Sung</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kangdong Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duman Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Singon Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Huro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KyungMuk Choi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyunghee University Hospital at Gangdong</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyujung Ahn</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyunghee University Medical center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Woosik Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MoonKyu Lee, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HyeSeung Jung</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanghak Lee</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SangHyun Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SangHong Baik</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Uijeongbu St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HyunSik Son</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of korea, Yeouido St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HyukSang Kwon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ajou University hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DaeJung Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wonju Severance Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byungsoo Yoo</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2013</study_first_submitted>
  <study_first_submitted_qc>September 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <last_update_submitted>February 2, 2015</last_update_submitted>
  <last_update_submitted_qc>February 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Hyperlipidemia, Familial Combined</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

